<DOC>
	<DOC>NCT00190892</DOC>
	<brief_summary>This trial will assess any efficacious benefit and any safety issues associated with the concomitant use of olanzapine and carbamazepine for the treatment of patients with bipolar I disorder, manic or mixed episodes</brief_summary>
	<brief_title>Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>1. Have a diagnosis of bipolar disorder and currently meet DSMIVTR criteria for a manic or mixed episode 2. Female patients must test negative on a serum pregnancy test at the time of enrollment and agree to use medically accepted contraception throughout the study. 3. Have YMRS score &gt; or = 20 at both the screening (Visit 1) and randomization (Visit 2) visits. 1. Have participated (been randomized) in a clinical trial of another investigational drug (including olanzapine or carbamazepine) within 30 days prior to Visit 1 2. Have a history of agranulocytosis (absolute neutrophil count&lt; 500/uL) during the patient's lifetime 3. Have acute, serious or unstable medical conditions, including (but not limited to) inadequately controlled diabetes (HgbA1c&gt;8%); severe hypertriglyceridemia (fasting triglycerides &gt; or = 500 mg/dl;hepatic insufficiency (specifically any degree of jaundice); recent cerebrovascular accidents; uncontrolled seizure disorders; serious acute systemic infection or immunologic disease: unstable cardiovascular disorders (including ischemic heart disease); or renal, gastroenterologic, respiratory, endocrinologic, neurologic, or hematologic diseases (specifically current absolute neutrophil count , &lt;1500/uL) 4. Have a substance dependence (except nicotine or caffeine), based on DSMIVTR criteria, within the 30 days prior to study entry. 5. Require concomitant treatment with any other medication with primarily central nervous system (CNS) activity, other than those allowed in the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>